Literature DB >> 30045266

Preoperative assessment of axillary lymph node status in breast cancer patients by ultrasonography combined with mammography: A STROBE compliant article.

Qun Liu1, Peng Xing, Huiting Dong, Tingting Zhao, Feng Jin.   

Abstract

Preoperative assessment of nodal stage is of importance in breast cancer treatment decision-making. This study was done to determine the power of combined mammography and ultrasonography in differentiating N0-N1 from N2-N3 breast cancer.We retrospectively reviewed clinical data of 3944 female patients with invasive breast cancer by preoperative mammography and ultrasonography between January 2006 and December 2013 at our hospital. Pathological diagnosis was available for each patient. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of mammography alone, ultrasonography alone, and combination of them for assessment of axillary lymph node (ALN) status were calculated, using definitive histological results as the baseline.The sensitivity, specificity, PPV, NPV, and accuracy was 90.4%, 68.2%, 36.5%, 97.2%, and 71.9% for ultrasonography; was 66.9%, 80.8%, 41.3%, 92.3%, and 78.4% for mammography; and was 94.9%, 62.4%, 33.8%, and 98.4% for combined mammography and ultrasonography. For combination, accuracy and the area under the receiver operating characteristic curve was 67.9% and 0.85, respectively.In conclusion, combining ultrasonography and mammography improves the sensitivity in differentiating N0-N1 breast cancer from N2-N3 breast cancer, but leading to a reduced specificity. Addition of mammography to ultrasonography seems not to provide significant benefits in predicting ALN status in breast cancer patients.

Entities:  

Mesh:

Year:  2018        PMID: 30045266      PMCID: PMC6078763          DOI: 10.1097/MD.0000000000011441

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Breast cancer is the most common malignancy among females in the world, with over 1 million new cases every year.[ Effective treatment options for breast cancer include surgery, local radiation, and systemic chemotherapy. Due to its radical nature, surgery has now been reduced to a minimum by the use of breast-conserving procedures[ and axillary lymph node (ALN) dissection.[ Lymph node status is an important prognostic factor for breast cancer.[ Nodal stage also affects the selection of adjuvant therapeutic modalites.[ Patients with N2 or greater disease have an increased risk of locoregional recurrence and postmastectomy radiotherapy should be considered for those patients.[ By contrast, N1 patients have been found to receive few benefits from adjuvant radiotherapy.[ Therefore, preoperative characterization of nodal stage is of clinical significance in breast cancer treatment decision-making. Several imaging techniques are currently available for preoperative assessment of lymph node status, including mammography, ultrasonography, magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT).[ Axillary ultrasonography is useful in excluding N2 and N3 invasive ductal metastases.[ However, an axillary ultrasound fails to accurately differentiate between pN1 and pN2pN3 breast cancer.[ The aim of this study is to determine the power of combined mammography and ultrasonography in differentiating N0 (negative axillary nodes) and N1 disease from N2 and N3 disease.

Materials and methods

Patients

From January 2006 to December 2013, a total of 3944 female patients were diagnosed as invasive breast cancer by preoperative mammography and ultrasonography and then received sentinel lymph node biopsy or modified radical mastectomy in the First Hospital of China Medical University (Shenyang, China). Pathological diagnosis was available for each patient. Clinical data including age, body mass index (BMI), tumor stage, and tumor molecular subtype were retrieved from medical records. Patients with previous surgery, neochemotherapy, multicentric lesions, recurrent breast cancer, or palpable lymph nodes were excluded. This study was approved by the Ethics Committee of the First Hospital of China Medical University.

Assessment of ALNs by mammography and ultrasonography

For mammography, standard craniocaudal (CC) and mediolateral oblique (MLO) images were obtained with further magnifications or additional views taken as required. Bilateral whole-breast ultrasonography was performed by experienced breast sonographers using 7- to 14-MHz linear probes (Hitachi Preirus, Tokyo, Japan). Mammographic and ultrasonographic findings were classed as normal/probably benign, equivocal, and suspicious of metastasis. On mammograms, a normal (probably benign) lymph node had an oval shape (long/short diameter ratio >2) with a clear, smooth border and a lymph node suspected of having metastasis showed a thickened cortex and evident calcification. On ultrasonograms, a lymph node with oval-shaped structures with an echogenic hilum was defined as normal or probably benign and one with an irregular morphology, cortical thickening, and compressed or displaced hilum was defined as suspicious metastasis. All mammography and ultrasonography examinations were confirmed by histological studies.

Data analysis

The associations between clinicopathological parameters and ALN metastasis were examined using multiple logistic regression analysis. Sensitivity (percentage of patients with true lymph node metastases who were diagnosed with ultrasound or mammography or both), specificity (the percentage of patients with pathologically proven node-negative patients who were truly no lymph node metastases in ultrasound or mammography or both), positive predictive value (PPV) (percentage of patients with pathologically confirmed metastases in patients with lymph node metastasis in ultrasound or mammography or both), negative predictive value (NPV) (percentage of patients with pathologically confirmed no metastases in patients with no lymph node metastasis in ultrasound or mammography or both), and accuracy of mammography alone, ultrasonography alone, and combination of them for detection of ALN metastasis were calculated. Receiver operating characteristic (ROC) curves were plotted and the area under the ROC curve (AUC) was calculated to compare the diagnostic power of ultrasonography and mammography alone or in combination. All statistical analyses were conducted using SPSS version 16.0 (SPSS Inc, Chicago, IL). When the P value was <.05, difference was considered statistically significant.

Results

Clinicopathological characteristics

The clinicopathological characteristics of the patients studied are shown in Table 1. About half of the patients (47.2%) were aged <50 years; 52.8% of the patients were aged ≥50 years. T1 tumors (tumor ≤20 mm in greatest dimension) were detected in 962 patients, T2 tumors (tumor >20 mm but ≤50 mm in greatest dimension) in 2596 patients, and T3 tumors (tumor >50 mm in greatest dimension) in 386 patients; 2410 patients (61.1%) showed N0 disease, 870 patients (22.1%) N1, 397 patients (10.1%) N2, and 267 patients (0.00057%) N3. The mean BMI was 24.8 kg/m2 (range 15.2–40.5), with 3411 patients (86.5%) having a BMI of ≥23 kg/m2. The majority of these patients had luminal tumors (70.4%), 13.8% HER-2-overexpressing tumors, and 15.9% triple-negative tumors.
Table 1

The clinicopathological characteristics of patients.

The clinicopathological characteristics of patients.

Associations of clinicopathological factors with ALN metastasis

We analyzed the associations of the patient clinicopathological features with ALN metastasis status (Table 2). Patient's age (P < .001), tumor size (P < .001), and tumor molecular subtype (P = .01) were significantly associated with ALN metastasis. No correlation was observed between patient's BMI and ALN metastasis (P = .45).
Table 2

Associations of ALN metastasis with clinicopathological parameters.

Associations of ALN metastasis with clinicopathological parameters.

Diagnostic performance of ultrasonography and mammography alone or in combination

We explored the diagnostic performance of ultrasonography and mammography, alone or in combination, for prediction of ALN metastasis. A positive diagnosis of ALN metastasis was defined as the presence of indeterminate or malignant nodes on ultrasonography or mammography. Of the 2300 normal/probably benign lesions based on preoperative ultrasonography, 1962 cases (85.3%) were identified as pN0, 274 (11.9%) pN1, 49 (2.1%) pN2, and 15 (0.7%) pN3 (Table 3). Of the 1644 patients who were suspected of having ALN metastasis based on preoperative ultrasonography, 448 (27.3%) did not actually have ALN metastasis and 596 (36.3%) had pN1 disease and 600 (36.4%) had pN2 or pN3 disease based on pathological examination. Figure 1 demonstrates the AUCs for ultrasonography, mammography, and combination of them. The sensitivity, specificity, PPV, NPV, accuracy, and AUC of ultrasonography for distinguishing between N0–N1 and N2–N3 disease was 90.4%, 68.2%, 36.5%, 97.2%, 71.9%, and 0.83%, respectively (Table 4).
Table 3

Assessment of axillary lymph node status by imaging tests.

Figure 1

The area under the receiver operating characteristic curve of combined mammography and ultrasonography.

Table 4

Performance of different imaging modalities in differentiating N0–N1 breast cancer from N2–N3 disease.

Assessment of axillary lymph node status by imaging tests. The area under the receiver operating characteristic curve of combined mammography and ultrasonography. Performance of different imaging modalities in differentiating N0–N1 breast cancer from N2–N3 disease. As shown in Table 3, 2197 (76.6%) of the 2869 patients who were identified to have normal/probably benign lesions by mammography had no evidence of ALN metastasis on pathological diagnosis. A total of 1075 patients were diagnosed as suspicious of metastasis by mammography. Of them, 213 patients (19.8%) were identified as pN0, 418 (38.9%) pN1, and 444 (41.3%) pN2 or greater. The sensitivity, specificity, PPV, NPV, accuracy, and AUC were 66.9%, 80.8%, 41.3%, 92.3%, 78.4%, and 0.74%, respectively (Table 4). Based on the combination of ultrasonography and mammography, 2082 cases were diagnosed as normal or benign (Table 3). Among them, 1849 cases (88.8%) were pN0, 199 (9.6%) pN1, and 34 (1.6%) pN2 or pN3. Of the 1862 cases who presented suspicious metastasis on combined ultrasonography and mammography, 561 cases (30.1%) were pN0, 371 (36.1%) pN1, and 630 (33.8%) pN2 or pN3. The sensitivity, specificity, PPV, NPV, accuracy, and AUC were 94.9%, 62.4%, 33.8%, 98.4%, 67.9%, and 0.85%, respectively (Table 4).

Discussion

Preoperative axillary staging is critical for determining prognosis and for making treatment decision in patients with invasive breast cancer. Ultrasonography is the primary imaging modality for assessment of axillary nodes. An et al[ compared the diagnostic performance of 18F-fluorodeoxyglucose (FDG) PET/CT, ultrasonography, and MRI in detecting ALN metastasis in 215 breast cancer patients. They found no significant difference in diagnostic ability among the imaging modalities, with the sensitivity of 72.3%, specificity of 77.3%, and accuracy of 75.3% for ultrasonography. However, the sensitivity of preoperative imaging modalities in identifying lymph node metastasis still needs to be improved. Seok et al[ retrospectively reviewed 104 breast cancer patients with clinically negative ALN using ultrasonography, FDG PET, and MRI and found that 21 patients of them (20.2%) were proven to have ALN metastasis. Combined ultrasonography and MRI has been documented to improve the accuracy of ALN staging in breast cancer patients, compared with ultrasonography or MRI alone.[ In several other types of malignancies, combination of different imaging techniques also improves diagnostic performance in assessment of lymph node metastasis.[ Mammographic screening is of clinical significance in identifying individuals with high-risk breast cancer. A combination of mammography and breast ultrasound has been found to offer additional benefits of breast cancer screening.[ These findings encourage us to evaluate the ability of combined mammography and ultrasonography to predict ALN status in invasive breast cancer patients. Breast positioning is the key factor affecting the image quality of mammography.[ Optimal positioning for CC and MLO views is important to improve the diagnostic performance of mammography. Despite these efforts, mammography has a limited capacity to identify abnormal ALNs.[ Our data revealed that the sensitivity of mammography for detection of ALN metastasis was only 66.9%; but, the specificity was as high as 80.8%. This finding is consistent with a previous study.[ Due to relatively high specificity, mammography is still commonly used for preoperative evaluation of ALN status. In comparison with mammography, ultrasonography had a higher sensitivity (90.4%) but lower specificity (68.2%) for predicting ALN metastasis in our patients. Ultrasound examination combined with fine-needle aspiration has been reported to increase the specificity to 100% but decrease the sensitivity to 53%.[ Another study reported similar findings that ultrasonography-guided fine-needle aspiration had a low sensitivity (39.5%) and high specificity (95.7%) for detecting ALN metastasis.[ Our data showed that combination of mammography and ultrasonography resulted in an increased sensitivity (94.9% vs 90.4%) and modestly decreased specificity (62.4% vs 68.2%), compared to ultrasonography alone. The accuracy for differentiating N0 and N1 disease from N2 and N3 disease was similar between ultrasonography alone and mammography/ultrasonography combination. Although combination of ultrasonography and mammography modestly increased the sensitivity for evaluating ALN status, the specificity was not elevated, but undesirably decreased. Therefore, addition of mammography seems not to offer significant benefits in preoperative ALN staging. However, this is a retrospective study based on clinical data from a signal center. The presence of inherent selection bias may compromise our conclusions.

Conclusion

In conclusion, our data show that combining ultrasonography and mammography would be favorable to improve the sensitivity in differentiating N0–N1 breast cancer from N2–N3 breast cancer, but leading to a reduced specificity. The potential benefit of mammography as an adjuvant to preoperative ultrasonography needs to be further explored.

Author contributions

Conceptualization: Qun Liu, Peng Xing, Feng Jin. Data curation: Qun Liu, Peng Xing. Formal analysis: Qun Liu, Peng Xing, Huiting Dong, Tingting Zhao, Feng Jin. Investigation: Qun Liu, Peng Xing, Huiting Dong, Tingting Zhao, Feng Jin. Methodology: Qun Liu, Peng Xing, Huiting Dong, Tingting Zhao, Feng Jin. Project administration: Qun Liu, Peng Xing, Huiting Dong. Resources: Qun Liu, Peng Xing, Huiting Dong. Software: Qun Liu, Peng Xing, Huiting Dong. Supervision: Qun Liu, Peng Xing, Huiting Dong, Tingting Zhao, Feng Jin. Validation: Qun Liu, Peng Xing, Huiting Dong, Tingting Zhao, Feng Jin. Visualization: Qun Liu, Peng Xing, Huiting Dong, Tingting Zhao, Feng Jin. Writing – original draft: Qun Liu. Writing – review and editing: Feng Jin.
  22 in total

Review 1.  Management of the regional lymph nodes following breast-conservation therapy for early-stage breast cancer: an evolving paradigm.

Authors:  Laura E G Warren; Rinaa S Punglia; Julia S Wong; Jennifer R Bellon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-18       Impact factor: 7.038

Review 2.  Treatment of breast cancer.

Authors:  Karen L Maughan; Mark A Lutterbie; Peter S Ham
Journal:  Am Fam Physician       Date:  2010-06-01       Impact factor: 3.292

3.  Accuracy of axillary lymph node staging in breast cancer patients: an observer-performance study comparison of MRI and ultrasound.

Authors:  Hiroyuki Abe; David Schacht; Kirti Kulkarni; Akiko Shimauchi; Ken Yamaguchi; Charlene A Sennett; Yulei Jiang
Journal:  Acad Radiol       Date:  2013-11       Impact factor: 3.173

4.  Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging.

Authors:  Stephanie A Valente; Gary M Levine; Melvin J Silverstein; Jessica A Rayhanabad; Janie G Weng-Grumley; Lingyun Ji; Dennis R Holmes; Richard Sposto; Stephen F Sener
Journal:  Ann Surg Oncol       Date:  2012-01-07       Impact factor: 5.344

Review 5.  Breast Cancer: Epidemiology and Etiology.

Authors:  ZiQi Tao; Aimin Shi; Cuntao Lu; Tao Song; Zhengguo Zhang; Jing Zhao
Journal:  Cell Biochem Biophys       Date:  2015-06       Impact factor: 2.194

6.  Axillary ultrasound for preoperative nodal staging in breast cancer patients: is it of added value?

Authors:  R J Schipper; L M van Roozendaal; B de Vries; R M Pijnappel; R G H Beets-Tan; M B I Lobbes; M L Smidt
Journal:  Breast       Date:  2013-10-02       Impact factor: 4.380

7.  Sonographic evaluation of isolated abnormal axillary lymph nodes identified on mammograms.

Authors:  Mahesh K Shetty; Wendy S Carpenter
Journal:  J Ultrasound Med       Date:  2004-01       Impact factor: 2.153

8.  Should adjuvant radiotherapy to the supraclavicular fossa be routinely given in patients with breast conservative treatment?

Authors:  Chun-Wei Wang; Wen-Hong Kuo; King-Jen Chang; Chiun-Sheng Huang; Jason Chia-Hsien Cheng
Journal:  J Surg Oncol       Date:  2007-08-01       Impact factor: 3.454

9.  Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients.

Authors:  Y-S An; D H Lee; J-K Yoon; S J Lee; T H Kim; D K Kang; K S Kim; Y S Jung; H Yim
Journal:  Nuklearmedizin       Date:  2013-11-13       Impact factor: 1.379

10.  The Effects of Preoperative (18)F-FDG PET/CT in Breast Cancer Patients in Comparison to the Conventional Imaging Study.

Authors:  Young Jin Choi; Young Duck Shin; Yoon Hee Kang; Moon Soo Lee; Min Koo Lee; Byung Sun Cho; Yoon Jung Kang; Ju Seung Park
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

View more
  7 in total

1.  To Evaluate the Accuracy of Axillary Staging Using Ultrasound and Ultrasound-Guided Fine-Needle Aspiration Cytology (USG-FNAC) in Early Breast Cancer Patients-a Prospective Study.

Authors:  Rashpal Singh; S V S Deo; Ekta Dhamija; Sandeep Mathur; Sanjay Thulkar
Journal:  Indian J Surg Oncol       Date:  2020-10-19

2.  Detecting Abnormal Axillary Lymph Nodes on Mammograms Using a Deep Convolutional Neural Network.

Authors:  Frederik Abel; Anna Landsmann; Patryk Hejduk; Carlotta Ruppert; Karol Borkowski; Alexander Ciritsis; Cristina Rossi; Andreas Boss
Journal:  Diagnostics (Basel)       Date:  2022-05-29

3.  Axillary Needle Biopsy in the Era of American College of Surgeons Oncology Group (ACOSOG) Z0011: Institutional Experience With a Largely Urban Minority Population and Review of the Literature.

Authors:  Lydia Choi; Kimberly Ku; Wei Chen; Awni D Shahait; Steve Kim
Journal:  Cureus       Date:  2022-04-20

4.  Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using Mammography-Based Radiomics Method.

Authors:  Jingbo Yang; Tao Wang; Lifeng Yang; Yubo Wang; Hongmei Li; Xiaobo Zhou; Weiling Zhao; Junchan Ren; Xiaoyong Li; Jie Tian; Liyu Huang
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

5.  Prediction of Metastasis in the Axillary Lymph Nodes of Patients With Breast Cancer: A Radiomics Method Based on Contrast-Enhanced Computed Tomography.

Authors:  Chunmei Yang; Jing Dong; Ziyi Liu; Qingxi Guo; Yue Nie; Deqing Huang; Na Qin; Jian Shu
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244

6.  A Novel Seven Gene Signature-Based Prognostic Model to Predict Distant Metastasis of Lymph Node-Negative Triple-Negative Breast Cancer.

Authors:  Wenting Peng; Caijin Lin; Shanshan Jing; Guanhua Su; Xi Jin; Genhong Di; Zhiming Shao
Journal:  Front Oncol       Date:  2021-09-16       Impact factor: 6.244

Review 7.  Can We Identify or Exclude Extensive Axillary Nodal Involvement in Breast Cancer Patients Preoperatively?

Authors:  Martijn Leenders; Gaëlle Kramer; Kamar Belghazi; Katya Duvivier; Petrousjka van den Tol; Hermien Schreurs
Journal:  J Oncol       Date:  2019-11-22       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.